If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Friday broker round-up

Fri, 17th Feb 2017 09:19
(ShareCast News) - AstraZeneca: Jefferies reiterates Buy with a target price of 5250p.BT Group: Jefferies reiterates Hold with a target price of 325p.Standard Life: Macquarie reiterates Outperform with a target price of 450p.Cobham: Goldman Sachs reiterates Sell with a target price of 88p.Drax: JPMorgan reiterates Overweight with a target price of 410p.South32: Deutsche Bank reiterates Hold with a target price of 157p.Royal Dutch Shell: UBS reiterates Buy with a target price of 2500p.AstraZeneca: Shore reiterates Sell with a target price of 4525p.Kenmare Resources: Canaccord maintains Buy with a target price of 510p.UNITE Group: Numis reiterates Buy with a target price of 731p. Astrazeneca South32 Limited Drax BT Unite Kenmare Resources

Shares in this article

Related News

LONDON MARKET CLOSE: FTSE 100 up as US jobs data eases rate hike fears
4 hours ago

LONDON MARKET CLOSE: FTSE 100 up as US jobs data eases rate hike fears

(Alliance News) - European stocks soared on Thursday as weaker than expected US jobs figures dampened market worries of a near-term interest rate hike...

Market News BAE Systems + 15 more shares
Hutchmed drug approved in China for advanced gastric cancer
7 hours ago

Hutchmed drug approved in China for advanced gastric cancer

(Alliance News) - Hutchmed China Ltd on Thursday announced regulatory approval for savolitinib, brand name 'ORPATHYS', for a form of gastric cancer wi...

Pharmaceuticals Hutchmed + 1 more share